BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scales SJ, Gupta N, De Mazière AM, Posthuma G, Chiu CP, Pierce AA, Hötzel K, Tao J, Foreman O, Koukos G, Oltrabella F, Klumperman J, Lin W, Peterson AS. Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes. J Am Soc Nephrol 2020;31:2044-64. [PMID: 32764142 DOI: 10.1681/ASN.2019080829] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Pollak MR, Friedman DJ. APOL1-Associated Kidney Disease. Emery and Rimoin' s Principles and Practice of Medical Genetics and Genomics 2023. [DOI: 10.1016/b978-0-12-812534-2.00007-2] [Reference Citation Analysis]
2 Andrews M, Yoshida T, Henderson CM, Pflaum H, McGregor A, Lieberman JA, de Boer IH, Vaisar T, Himmelfarb J, Kestenbaum B, Chung JY, Hewitt SM, Santo BA, Ginley B, Sarder P, Rosenberg AZ, Murakami T, Kopp JB, Kuklenyik Z, Hoofnagle AN. Variant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury. PLoS One 2022;17:e0276649. [PMID: 36279295 DOI: 10.1371/journal.pone.0276649] [Reference Citation Analysis]
3 Daneshpajouhnejad P, Kopp JB, Winkler CA, Rosenberg AZ. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat Rev Nephrol 2022. [PMID: 35217848 DOI: 10.1038/s41581-022-00538-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gerstner L, Chen M, Kampf LL, Milosavljevic J, Lang K, Schneider R, Hildebrandt F, Helmstädter M, Walz G, Hermle T. Inhibition of endoplasmic reticulum stress signaling rescues cytotoxicity of human apolipoprotein-L1 risk variants in Drosophila. Kidney International 2022. [DOI: 10.1016/j.kint.2021.12.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Tzukerman M, Shamai Y, Abramovich I, Gottlieb E, Selig S, Skorecki K. Comparative Analysis of the APOL1 Variants in the Genetic Landscape of Renal Carcinoma Cells. Cancers (Basel) 2022;14:733. [PMID: 35159001 DOI: 10.3390/cancers14030733] [Reference Citation Analysis]
6 Kruzel-davila E, Bavli-kertselli I, Ofir A, Cheatham AM, Shemer R, Zaknoun E, Chornyy S, Tabachnikov O, Davis SE, Khatua AK, Skorecki K, Popik W. Endoplasmic reticulum-translocation is essential for APOL1 cellular toxicity. iScience 2022;25:103717. [DOI: 10.1016/j.isci.2021.103717] [Reference Citation Analysis]
7 Pays E. Distinct APOL1 functions in trypanosomes and kidney podocytes. Trends Parasitol 2021:S1471-4922(21)00285-3. [PMID: 34887168 DOI: 10.1016/j.pt.2021.11.005] [Reference Citation Analysis]
8 Yoshida T, Latt KZ, Heymann J, Kopp JB. Lessons From APOL1 Animal Models. Front Med (Lausanne) 2021;8:762901. [PMID: 34765626 DOI: 10.3389/fmed.2021.762901] [Reference Citation Analysis]
9 McCarthy GM, Blasio A, Donovan OG, Schaller LB, Bock-Hughes A, Magraner JM, Suh JH, Tattersfield CF, Stillman IE, Shah SS, Zsengeller ZK, Subramanian B, Friedman DJ, Pollak MR. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease. Dis Model Mech 2021;14:dmm048952. [PMID: 34350953 DOI: 10.1242/dmm.048952] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
10 Kon V, Yang HC, Smith LE, Vickers KC, Linton MF. High-Density Lipoproteins in Kidney Disease. Int J Mol Sci 2021;22:8201. [PMID: 34360965 DOI: 10.3390/ijms22158201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Ultsch M, Holliday MJ, Gerhardy S, Moran P, Scales SJ, Gupta N, Oltrabella F, Chiu C, Fairbrother W, Eigenbrot C, Kirchhofer D. Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif. Commun Biol 2021;4:916. [PMID: 34316015 DOI: 10.1038/s42003-021-02387-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Blessing NA, Wu Z, Madhavan SM, Choy JW, Chen M, Shin MK, Hoek M, Sedor JR, O'Toole JF, Bruggeman LA. Lack of APOL1 in proximal tubules of normal human kidneys and proteinuric APOL1 transgenic mouse kidneys. PLoS One 2021;16:e0253197. [PMID: 34138902 DOI: 10.1371/journal.pone.0253197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Freedman BI, Kopp JB, Sampson MG, Susztak K. APOL1 at 10 years: progress and next steps. Kidney Int 2021;99:1296-302. [PMID: 33794228 DOI: 10.1016/j.kint.2021.03.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
14 Bruggeman LA, Sedor JR, O'Toole JF. Apolipoprotein L1 and mechanisms of kidney disease susceptibility. Curr Opin Nephrol Hypertens 2021;30:317-23. [PMID: 33767059 DOI: 10.1097/MNH.0000000000000704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Goyal R, Singhal PC. APOL1 risk variants and the development of HIV-associated nephropathy. FEBS J 2021;288:5586-97. [PMID: 33340240 DOI: 10.1111/febs.15677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Pays E. The Mechanism of Kidney Disease Due to APOL1 Risk Variants. J Am Soc Nephrol 2020;31:2502-5. [PMID: 32943491 DOI: 10.1681/ASN.2020070954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Gupta N, Wang X, Wen X, Moran P, Paluch M, Hass PE, Heidersbach A, Haley B, Kirchhofer D, Brezski RJ, Peterson AS, Scales SJ. Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes. J Am Soc Nephrol 2020;31:2065-82. [PMID: 32764138 DOI: 10.1681/ASN.2019080830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]